The administration of growth hormone-releasing hormone (GHRH), an inducer of IGF-1, has been clinically confirmed to ameliorate cognitive impairment by increasing levels of N-acetylaspartyl-glutamate (NAAG) and GABA in AD patients [143,144]. This evidence concerns the gene IGF1 and Alzheimer disease.